Publication of Prospectus

RNS Number : 8939X
Oxford Biomedica PLC
14 December 2010
 



THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL

 

This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any New Ordinary Shares, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract or commitment whatsoever with respect to the proposed Firm Placing and Placing and Open Offer or otherwise. This announcement is not a prospectus and investors should not subscribe for or purchase any New Ordinary Shares referred to in this announcement except SOLELY on the basis of information in the prospectus THAT WAS published ON 13 DECEMBER 2010. Copies of the prospectus will, following publication, be available from Oxford BioMedica's head office at Medawar Centre, Robert Robinson Avenue, The Oxford SCIENCE Park, Oxford, OX4 4GA

 

 

OXFORD BIOMEDICA PLC

 

PUBLICATION OF PROSPECTUS AND CIRCULAR

 

Oxford BioMedica plc ("Oxford BioMedica" or the "Company") announces that, further to the announcement on 13 December 2010 in relation to the Firm Placing and Placing and Open Offer (the "Transaction") to raise £20 million before expenses, a Prospectus relating to the Transaction has been approved by the UK Listing Authority (the "UKLA").

 

The Prospectus was posted to shareholders yesterday and copies of the Prospectus will be available for inspection at the UKLA's National Storage Mechanism, which can be found at www.hemscott.com.

 

In addition, the Prospectus is available to view on the Company's website (www.oxfordbiomedica.co.uk).  Copies of the Prospectus will be also available from the offices of Oxford BioMedica plc, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA and at the offices of Morrison & Foerster (UK) LLP, CityPoint, One Ropemaker Street, London EC2Y 9AW.

 

For further information please contact:

 

For further information, please contact:


Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Andrew Wood, Chief Financial Officer

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000



Singer Capital Markets Limited

Shaun Dobson/ Claes Spång

Tel: +44 (0)20 3205 7500

 

Media/Financial Enquiries:

Emma Thompson/Rob Newman/Amber Bielecka

M:Communications

 

Tel: +44 (0)20 7920 2345

 

 

US Enquiries:

Simon Harnest

The Trout Group LLC

 

Tel: +1 (646) 378 2900

 

This announcement is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada or Japan or any jurisdiction into which the publication or distribution would be unlawful.

 

This announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire shares in the capital of the Company in the United States, Australia, Canada or Japan or any jurisdiction in which such offer or solicitation would be unlawful.  Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.  The securities have not been and will not be registered under the United States Securities Act of 1933, as amended ("Securities Act") and may not be offered, sold or transferred, directly or indirectly, within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the securities laws of any state or other jurisdiction of the United States. The securities are being offered and sold outside the United States in accordance with Regulation S under the Securities Act.  No public offering of the shares referred to in this announcement is being made in the United States, Australia, Canada or Japan or any jurisdiction in which such public offering would be unlawful.

 

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

PDIDZLBFBLFLFBF